Search results for "molecular microbiology"

InterPlay Adenoviral C-Terminal Vector, part of the InterPlay Adenoviral TAP System, combines Agilent’s unique tandem affinity purification system with our exclusive adenoviral gene delivery system for enhanced gene delivery to a broader range of mammalian cells, higher protein yields, and improved purification and analysis of endogenous interacting protein partners. 

InterPlay Adenoviral C-Terminal Vector, part of the InterPlay Adenoviral TAP System, combines Agilent’s unique tandem affinity purification system with our exclusive adenoviral gene delivery system for enhanced gene delivery to a broader range of mammalian cells, higher protein yields, and improved purification and analysis of endogenous interacting protein partners. 

High Quality Assays with Reproducible and Reliable Results

Tripling NMR sensitivity within the budget

Tryosine kinase inhibitor and epigenetic modifier; Inhibits PDGF, FGF, EGF, TGFß, SIRT1, and SIRT5

RHO/ROCK pathway inhibitor; Inhibits ROCK2

Fractalkine

BMP pathway inhibitor; Inhibits ALK1, ALK2, ALK3, and ALK6

The Dursan surface treatment uses a functionalized, silica-like coating for stainless steel frits and column tubes. The coating is very robust and thin (~400 - 1600nm) that modifies the contact surface your analytes meet to be metal-free and somewhat hydrophobic.  

Engineered, homologous, and specific target cells that enable screening for antibody-induced effector functions.

New service gives all researchers exclusive access to liquid biopsy-based tools

New liquid biopsy test can identify 70 of the most commonly mutated genes in solid tumours, as well as microsatellite instability

Multiplex biochemical assays, sometimes customized, help develop the toxicity profile and selection of agrochemicals before they enter the R&D process

Read on for the highlights of the Q&A session from part one of the series: Identification of Iodinated Disinfection Byproducts by GC-MS/MS

therascreen® EGFR RGQ PCR Kit to guide treatment with AstraZeneca’s lung cancer drug in U.S.

QIAGEN Clinical Insight® bioinformatics offering allows clinical labs to interpret and report genomic variants will be demonstrated at upcoming ClinGen, ASCO and ESHG meetings